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Contribution of JAK2 mutations to T-cell lymphoblastic
lymphoma development
AM Roncero1,2,10, P López-Nieva1,2,10, MA Cobos-Fernández1,2,3,10, M Villa-Morales1,2,3, L González-Sánchez1,2,3, JL López-Lorenzo2,
P Llamas2, C Ayuso2,3, SM Rodríguez-Pinilla2, MC Arriba1,2, MA Piris4, P Fernández-Navarro5,6,7, AF Fernández8, MF Fraga8,9,
J Santos1,2,3 and J Fernández-Piqueras1,2,3
The JAK-STAT pathway has a substantial role in lymphoid precursor cell proliferation, survival and differentiation. Nonetheless, the
contribution of JAK2 to T-cell lymphoblastic lymphoma (T-LBL) development remains poorly understood. We have identiﬁed one
activating TEL-JAK2 translocation and four missense mutations accumulated in 2 out of 16 T-LBL samples. Two of them are novel
JAK2 mutations and the other two are reported for the ﬁrst time in T-LBL. Notably, R683G and I682T might have arisen owing to
RNA editing. Mutated samples showed different mutated transcripts suggesting sub-clonal heterogeneity. Functional approaches
revealed that two JAK2 mutations (H574R and R683G) constitutively activate JAK-STAT signaling in γ2A cells and can drive the
proliferation of BaF3-EpoR cytokine-dependent cell line. In addition, aberrant hypermethylation of SOCS3 might contribute to
enhance the activation of JAK-STAT signaling. Of utmost interest is that primary T-LBL samples harboring JAK2 mutations exhibited
increased expression of LMO2, suggesting a mechanistic link between JAK2 mutations and the expression of LMO2, which was
conﬁrmed for the four missense mutations in transfected γ2A cells. We therefore propose that active JAK2 contribute to T-LBL
development by two different mechanisms, and that the use of pan-JAK inhibitors in combination with epigenetic drugs should be
considered in future treatments.
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INTRODUCTION
Precursor T-cell lymphoblastic neoplasms are aggressive hemato-
logical malignancies consisting of small- to medium-sized blast
cells, which mainly develop in children (in particular adolescent
males) but can also affect adults. Most often, these malignancies
manifest with extensive marrow and blood affectation (called
acute T-cell lymphoblastic leukemia, T-ALL), and less commonly as
a mass lesion in the thymus/anterior mediastinum or in lymph
nodes, with less than 25% marrow blasts (then called T-cell
lymphoblastic lymphoma, T-LBL).1 The molecular basis of these
neoplasms has been well established in T-ALL,2,3 but to a lesser
extent in T-LBL.4,5
It is well known that the JAK-STAT pathway has a substantial
role in lymphoid precursor cell proliferation, survival and
differentiation.6 Thus, it was not surprising that hematological
malignancies had been associated with aberrant JAK-STAT
signaling transduction.7 In fact, several authors reported activating
mutations of two members of the Janus family of tyrosine kinases,
JAK1 (4–18%) and JAK3 (5%), in a fraction of T-ALLs.8–11
Notwithstanding, aberrant JAK-STAT signaling transduction was
ﬁrst reported in T-ALL exhibiting the t(9;12) (p24;p13) transloca-
tion, a rare rearrangement resulting in the constitutively active
TEL-JAK2 kinase fusion oncoprotein.12 This fact, together with the
discovery of activating mutations of JAK2 in other hematological
malignancies, such as myeloproliferative neoplasms,13,14 in
particular the gain-of-function substitution of valine to phenyla-
lanine at codon 617 at the pseudokinase domain of JAK2 found in
patients with polycythemia vera,15,16 showed the clinical relevance
of this gene given more attention on the grounds of potential
involvement in T-cell lymphoblastic leukemia/lymphoma. Whether
acquisition of JAK2 mutations is an important event in the
pathogenesis of these neoplasms is still unclear. To explore this
possibility, we performed a mutational screening of this gene in a
new sample series of T-LBLs.
As JAK2 mediates crucial physiological events, its activity is
tightly regulated through additional mechanisms. It is well known
that dephosphorylation of JAK2 by protein-tyrosine-phosphatases,
such as SHP1,17 and recruitment of negative regulators, such as
suppressors of cytokine signaling (SOCS) proteins, are involved in
the downregulation of JAK-STAT signaling by different
mechanisms.7,18 SOCS proteins are silenced in many tumors by
hypermethylation of CpG islands at their promoters. Reduced
SOCS1 expression is a frequent event in certain types of
lymphoma and myelodysplastic syndrome,19,20 including patients
who harbor an activating JAK2 mutation.21 Another member of
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the same protein family, SOCS3, binds and directly inhibits the
catalytic domains of JAK1 and JAK2 proteins,22 and reduced
expression of SOCS3 has been reported in various human cancers
associated with constitutive STAT3 activation.23 To assess for the
possible contribution of these negative regulators in activating the
JAK-STAT pathway, we studied the methylation density and the
distribution of methylated CpG sites at the promoters of SHP1,
SOCS1 and SOCS3.
On the other hand, recent studies have demonstrated a
nuclear role for JAK2 activation in regulation of LMO2.24
LMO2 is essential for normal hematopoiesis development
and has been implicated as a potent oncogene in a subset
of T-cell lymphoblastic leukemia.25–28 Transfection of JAK2
into JAK2-null γ2A cells demonstrated the nuclear localization
of JAK2 to induce an epigenetic control of LMO2 expression.
In line with this observation, LMO2 has been reported as
one of the genes whose messenger RNA levels were most
decreased by inhibition of JAK2.24 Therefore, we also explored
whether JAK2 activating mutations identiﬁed in our sample




Sixteen human T-LBL samples (eight pediatric and eight from adult
patients), and four thymuses of human fetus without pathology, were
provided by the following Biobanks integrated in the Spanish Hospital
Biobanks Network (RetBioH; www.redbiobancos.es): i+12 Biobank in the
Hospital 12 de Octubre (samples 226 and 829), Hospital Universitario Ramón
y Cajal-IRYCIS Biobank (sample 346), Hospital Virgen de la Salud Biobank in
Toledo Medical Center (samples 188 and 192), Complejo Hospitalario de
Vigo Biobank (sample 521), Hospital General Universitario Gregorio Marañón
Biobank (samples 038, 080, 135, 154, 460 and 685), Hospital de La Paz
Biobank (samples 238 and 408) and Complejo Hospitalario Universitario de
Santiago Biobank (samples 516 and 731-4). The samples and associated
data were processed and released following standard operation
procedures with appropriate approval by Ethical and Scientiﬁc Commit-
tees. Lymphomas were diagnosed according to World Health Organization
Classiﬁcation of Hematological Malignancies and recommendations from
the European childhood lymphoma pathology panel.29,30 When adequate
material was available, additional markers were added to improve the sub-
classiﬁcation of T-LBLs (Supplementary Table S1). Institutional review board
approval was obtained for these studies (reference CEI 31-773).
The participants provided written informed consent in accordance with
the Declaration of Helsinki.
Figure 1. TEL-JAK2 translocation and mutational analysis of JAK2. (a) Schematic representation of the fusion protein resulting from the t(9;12)
(p24;p13) translocation. (b) PCR ampliﬁcation of cDNA from a representation of the samples and HEK293T transfected with TEL-JAK2 positive
control, using primers covering the breakpoint of this translocation. (c) Western blot analysis of STAT5 and phospho-Y694-STAT5 in T-LBLs and
fetal thymus as control (CT). (d) Schematic representation of JAK2 protein showing all validated mutations at pseudokinase domain.
All mutations were found in two T-LBL samples, both of them exhibiting several transcript variants.
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Screening for TEL-JAK2 translocation
Identiﬁcation of TEL-JAK2 translocations was performed by PCR ampliﬁca-
tion of cDNA using speciﬁc primers12,31 (Figure 1; Supplementary Table S2).
To obtain a positive control, we transfected HEK 293T cells (American Type
Culture Collection, ATCC; Manassas, VA, USA) with TEL-JAK2 cDNA cloned
into pcDNA3 expression vector (a gift from Dr. Olivier Bernard at the
Institute National de la Santé et de la Recherche Médicale, France) using
Lipofectamine Reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA).
Mutational analysis of JAK2
Reverse transcription was carried out using SuperScript First-Strand
Synthesis System for RT-PCR (Invitrogen) followed by PCR with the Fast
Start High Fidelity PCR System (Roche Applied Science, Basel, Switzerland).
PCR fragments expanding mutational hot spots of this gene from exons 12
to 16 were cloned into pGEM-T Easy Vector (Promega, Life Technologies,
Carlsbad, CA, USA). Mutation analysis of JAK2 was performed in 20 cDNA
clones of each tumor sample by direct sequencing. The presence of
speciﬁc mutations at either genomic or transcriptomic level was validated
by pyrosequencing analysis. The set of primers for PCR ampliﬁcation were
designed with Vector NTI software (Life Technologies Corporation), and
primers for pyrosequencing were designed using the speciﬁc software
PyroMark assay design (version 2.0.01.15). Pyrosequencing was performed
using PyroMark Q24 reagents, and vacuum prep workstation, equipment
and software (Qiagen, Valencia, CA, USA). Primer sequences are indicated
in Supplementary Table S2.
Gene expression analysis
The expression of JAK2 and LMO2 genes was quantiﬁed at the transcript
level by real-time quantitative RT-PCR from total RNA using a two-step
procedure: ﬁrst the Transcriptor First Strand cDNA Synthesis Kit, then the
LightCycler FastStart DNA Master SYBR Green I (Roche). Expression values
of β2μG (beta-2-microglobulin) were used as reference. Primers are
described in Supplementary Table S2.
Protein expression was determined by western blot using the following
primary antibodies: Jak2 (D2E12) Rabbit mAb (Cell Signaling Technology,
Inc., Danvers, MA, USA), Phospho-Jak2 Tyr1007/1008 (C80C3) Rabbit mAb
(Cell Signaling), Stat5 Rabbit (Cell Signaling), Stat5 (pY694) (BD Biosciences,
San Jose, CA, USA), SOCS3 (ab16030) (Abcam, Cambridge, UK), β-Actin
mouse (AC-15) (Sigma, Saint Louis, MO, USA) and α-Tubulin mouse (DM1A)
(Sigma). Two secondary antibodies were used: anti-mouse IgG HRP-linked
antibody (Cell Signaling), and anti-rabbit IgG HRP-linked antibody (Cell
Signaling).
To investigate SOCS3 phosphorylation state (pSOCS3), ﬁrst, we
immunoprecipated SOCS3 using anti-SOCS3 antibody (ab3693) (Abcam),
and second, we analyzed pSOCS3 expression using anti-phosphotyrosine
(clone 4G10) (Upstate Biotecnology, Lake Placid, NY, USA), following the
protocol described by Elliot et al.32 Mouse TrueBlot ULTRA (Anti-Mouse Ig
HRP) (Rockland, Limerick, PA, USA) was as used as the secondary antibody.
Immunohistochemistry
JAK2 expression was detected by immunohistochemistry in fresh-frozen
tissue sections of two samples (238 and 460) using rabbit anti-JAK2,
(D2E12#3230) (Cell signalling Technology) as the primary antibody.
Polyclonal Goat Anti-Rabbit Immunoglobulin/HRP P0448 (Dako, Hamburg,
Germany) and Liquid DAB+Substrate Chromogen System K3467 (Dako)
were applied for visualization. Sections were counterstained with
hematoxylin (Sigma) and observed on an Axiovert 200 inverted
microscope (Zeiss, Göttingen, Germany). Images were acquired with a
color ccd monochrome camera (SPOT RT Slid) by Devices Zeiss MTB
Microscope software and processed with Fiji-Image J free software (http://
ﬁji.sc; National Institutes of Health, Bethesda, MD, USA).
Immunoﬂuorescence
Subcellular distribution of JAK2 protein was studied by immunoﬂuores-
cence in transfected γ2A cells (JAK2-deﬁcient human ﬁbrosarcoma cells
provided by Dr. Ana Costa Pereira, Imperial College, London) using rabbit
anti-JAK2, (D2E12) Rabbit mAb (Cell Signaling) as the primary antibody and
anti-rabbit Alex Fluor-488 (Invitrogen) as the secondary antibody. Images
were acquired with a Confocal LSM510 Zeiss microscope and processed
with Fiji-Imaje J free software (http://ﬁji.sc; National Institutes of Health).
Site-directed mutagenesis
Human PCR fragment from JAK2-cDNA was ampliﬁed using the primers
indicated in Supplementary Table S2 and cloned into the pcDNA3 vector
(Invitrogen). All JAK2 mutants were generated by PCR reactions with
QuikChange Lightning Site-Directed Mutagenesis kit (Agilent Technolo-
gies, Santa Clara, CA, USA).
In addition, JAK2-H574R and JAK2-R683G mutants were generated in
pEZ-Lv201 vector expressing human JAK2 (Genecopoeia, Rockville, MD,
USA) by PCR reactions with QuikChange II XL Site-Directed Mutagenesis kit
(Agilent Technologies).
Dual luciferase assays
The functional activity of JAK2 mutants was measured in γ2A cells by dual
luciferase assays (Promega) with the STAT5 luciferase reporter pGL4.52
[luc2P/STAT5 RE/Hygro] vector (Promega).33 Cells were seeded in 12-well
plates overnight and transiently co-transfected using siLentFect (Bio-Rad,
Hercules, CA, USA) with pGL4.52[luc2P/STAT5 RE/Hygro] vector, together
with STAT5A-pCMV6-XL4 and wild-type or mutant JAK2-pcDNA3 constructs.
pRLTK was always co-transfected as an internal control. The cells were
lysed in passive lysis buffer 24 h after transfection and luminescence was
recorded on a single tube luminometer (Sirius luminometer; Berthold,
Munich, Germany) following the manufacturer’s instructions.
Proliferation assays
Murine cytokine-dependent cells expressing erythropoietin (Epo) receptor
(BaF3-EpoR cells) were kindly gifted by Dr David M. Weinstock
(Dana-Farber Cancer Institute, Boston, MA, USA) and Dr Charles Mullighan
(St. Jude Children´s Research Hospital, Memphis, TN, USA). BaF3-EpoR cells
were transduced with lentiviral pEZ-Lv201 empty vector, pEZ-Lv201 JAK2
WT, pEZ-Lv201 JAK2 H574R and pEZ-Lv201 JAK2 R683G and selected for
stable expression of the constructs. Cells were sorted by FACS
(FACSCVantage SE; BD Biosciences) according to comparable levels of
GFP expression. Sorted cells were washed and seeded at 1 × 105 cells/ml in
medium deprived of Epo. Viable cells were counted every 24 h for four
consecutive days by trypan blue exclusion and the TC10 Automated Cell
Counter (Bio-Rad).
Methylation analysis of SHP1, SOCS1 and SOCS3 genes
Methylation-speciﬁc PCR was performed according to conventional
procedures based on bisulﬁte-mediated conversion of unmethylated
cytosines to uracil; genomic DNA (500 ng) was modiﬁed with sodium
bisulﬁte using kit Zymo EZ DNA Methylation Kit (Zymo Research, Orange,
CA, USA) in agreement with the instructions of the manufacturer. The set
of primers for PCR ampliﬁcation and sequencing were designed using the
Methyl primer Express software (Applied Biosystems, Foster City, CA, USA).
PCR fragments were cloned into pGEM-TEasy Vector (Promega).
A minimum of 8–10 colonies per sample was sequenced. The methylation
status of every CpG was determined using the Sequencing Analysis 5.2
Software from Applied Biosystems. Primers and conditions are indicated in
Supplementary Table S2. Some speciﬁc primers were as previously
described.34–36
Epigenetic studies of SOCS3 in cell lines
To induce DNA demethylation, Jurkat and Molt-4 cells (German Collection
of Microorganisms and Cell Cutures; DSMZ, Braunschweig, Germany) were
grown in the presence of 2.5 μM 5'-aza-cytidine (Sigma). The histone
deacetylase inhibitor trichostatin A (Sigma) was used at 1.0 μM and added
to the cultured cells for 24 h. Combined treatment with 5'-aza-cytidine and
trichostatin A was performed by incubating the cells with 5'-aza-cytidine
for 72 h, followed by a 24-h exposure to trichostatin A. Expression levels of
SOCS3 were quantiﬁed by real-time quantitative RT-PCR. Speciﬁc primers
are indicated in Supplementary Table S2.
Statistical analyses
The Shapiro-Wilk test was used to check expression data sets for normality,
and the Levene test was used for homogeneity of variances. Student's
t-test was used to compare gene expression mean values in controls and
experimental groups with Bonferroni correction for multiple comparisons.
These statistical analyses were performed using R software. All data
reported represent at least three independent replicates.
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RESULTS
One adult Pro-T-LBL sample exhibited activating TEL-JAK2 t(9;12)
(p24;p13) translocation
TEL-JAK2 fusion events have been associated with T-ALL, as well
as with atypical chronic myeloid leukemia.12 With the aim of
looking for TEL-JAK2 t(9;12)(p24;p13) translocation, we ampliﬁed
cDNA from all 16 lymphomas (Supplementary Table S1) using
appropriate primers (Supplementary Table S2). Ampliﬁcation from
HEK 293T cells transfected with a TEL-JAK2-cDNA pcDNA3
construct (resulting from a fusion between the 3´part of the
kinase (JH1) domain of JAK2 and the 5´region of Translocation Ets
Leukemia (TEL) gene,12 provided us with a positive control. Only
one TEL-JAK2 translocation was detected in only one patient with
adult Pro-T lymphoblastic lymphoma (829) (Figures 1a and b).
To determine the functional consequences of this translocation,
the status of STAT5 tyrosine phosphorylation was tested in
selected samples using an activation-speciﬁc STAT5 antibody that
selectively recognizes STAT5 phosphorylated at tyrosine 694
(pSTAT5). The sample harboring the TEL-JAK2 fusion protein
exhibits the highest levels of pSTAT5, suggesting constitutive
activation of the JAK-STAT signaling pathway. Stripping and
reprobing the membrane with an antibody that recognized
STAT5A and B showed differential STAT5 protein expression for
each tumor (Figure 1c).
Four missense substitutions in JAK2 were validated in two
pediatric T-LBL samples that exhibit sub-clonal heterogeneity
As activating mutations of JAK2 have been reported in other
hematological malignancies,13–16 we performed a mutational
screening of this gene in our sample series of T-LBLs.
A comparative study of the JAK2-cDNA sequence encoding exons
12 to 16, which cover the pseudokinase domain of JAK2 gene,
revealed eight sequence variants (single nucleotide variants) that
accumulate in two out of eight pediatric patients (460 and 734;
25%). Six of these variants were missense mutations and, to our
knowledge, four of them have not been previously reported for
JAK2 (E549K, I682T, H574R and K558R). Mutation L634P has been
reported in large intestine carcinoma (Catalogue of Somatic
Mutations in Cancer, COSMIC database; Id. COSM1462578);
mutation R683G has been reported in childhood B-precursor
acute lymphoblastic leukemia associated with Down's
syndrome37–41 (Figure 1d; Supplementary Figure S1).
Figure 2. Effects of the JAK2 mutations in inducing JAK/STAT pathway activation and in driving cytokine independence cell proliferation.
(a) JAK2-driven STAT5 transcriptional activity, measured by luciferase assay in γ2A cells transiently transfected with wild-type or four different
mutant JAK2, or empty vector as a control. A representative western blot of JAK2 can be seen under the bar chart. Error bars represent the
standard deviation (s.d.); *Po0.01. (b and c) BaF3-EpoR cells stably expressing WT-JAK2, H574R-JAK2 or R683G-JAK2 were washed and seeded
at 1 × 105 cells/ml in medium deprived of Epo. Viable and total cells were counted every 24 h for four consecutive days. (b) A graphical view of
cell proliferation for each cell line. Error bars represent the s.d.; *Po0.05 and ** Po0.01. (c) Bar representation of cell viability in percentage,
indicating the signiﬁcance between JAK2 variants within time points. (d) Representative western blot analysis of sorted BaF3-EpoR cells stably
expressing WT-JAK2, H574R-JAK2 or R683G-JAK2. Cells were maintained for 24 h in medium without Epo (Starving) and then stimulated or not
for 20min with 1 U/ml of Epo (Starving+Epo). Total levels or phosphorylation of JAK2 and STAT5 were analyzed by incubation with their
speciﬁc antibodies. Error bars represent the s.d.; *Po0.05 and **Po0.01.
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To further demonstrate the presence and frequency of these
mutations at the transcriptomic and genomic levels, we
performed pyrosequencing as a more sensitive targeted-deep-
sequencing approach to analyze PCR-ampliﬁed fragments cover-
ing mutation sites. Remarkably, we could validate the presence of
four mutants (H574R, L634P, I682T and R683G). In case of L634P,
cDNA analysis could not be possible because of the poor state of
cDNA material. Notably, two of the conﬁrmed mutations (R683G
and I682T) were not found at the genomic level, suggesting that
they have arisen by means of RNA-editing processes. It should be
stressed that pyrosequencing from cDNA was performed on
independent cDNA syntheses of samples 460 and 734.
Among the four conﬁrmed mutations, the most frequent was
R683G (at tumor 460), which appeared in 14.28% of cDNA clones.
However, pyrosequencing data revealed that the most common
mutation was H574R (at tumor 734), which appeared in 20.51% of
the genomes and in 21.6% of the JAK2 transcripts (Supplementary
Figure S1).
It should be noted that each mutation appears as unique to a
speciﬁc cDNA clone ('private' mutations). Furthermore, because
Figure 3. Methylation-speciﬁc PCR (MSP) for SHP1, SOCS1 and SOCS3 genes and methylation density at the SOCS3 promoter, in T-LBLs with
mutant JAK2. (a) Schematic depiction of the CpG-island around the transcription start site of the genes (long black arrow). Short vertical lines
represent CpG dinucleotides. (b) MSP analysis. The presence of a PCR band under lanes M or U indicated methylated or unmethylated CpG
islands. Normal lymphocytes (NL) and in vitro methylated DNA (IVD) were used as a positive control. (c) Methylation proﬁle of SOCS3 in two
fetal thymuses and T-LBLs harboring JAK2 genetic alterations. The presence of methylated (black squares) or unmethylated (white squares)
CpG sites is indicated in 10 sequenced clones for every tumor. Methylation density is indicated as the percentage of methylated sites.
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the two mutated T-LBL samples exhibited three or more sequence
variants, it would be reasonable to think of sub-clonal hetero-
geneity within these tumors.
Functional signiﬁcance of JAK2 mutants
To assist in the selection of conﬁrmed mutations, we used two
mutation effect prediction algorithms: PolyPhen-2 (http://genetics.
bwh.harvard.edu/pph2/) and SIFT (http://sift.bii.a-star.edu.sg/).
Because both algorithms returned predictions that showed some
discrepancies, we selected all four missense mutations for
functional analyses (Supplementary Table S3). To assess whether
JAK2 mutants are able to constitutively activate the JAK-STAT
signaling pathway, we performed dual luciferase assays in γ2A
JAK2-deﬁcient cells. Functional assays measuring luminescence in
γ2A cells co-transfected with JAK2-mutant constructs and STAT5-
luciferase reporter, revealed a tendency for JAK2 mutant variants
to drive STAT5-mediated luciferase to a higher expression levels
than the wild-type construct, this increase being statistically
signiﬁcant for two JAK2 mutants: R683G from lymphoma 460 and
H574R from lymphoma 734. As there are no apparent differences
in JAK2-protein levels between wild-type and JAK2 variants, this
factor should not disturb the interpretation of the data and their
statistical signiﬁcance (Figure 2a). It would therefore be reasonable
to think that at least these two mutations are able to constitutively
activate the JAK2-STAT5 signalling pathway. These results are in
agreement with a previous report that describes R683G as an
activating mutation.42
To further explore the functional consequences of the two
activating JAK2 mutations, we assess whether these mutations are
able to drive the proliferation of BaF3-EpoR cytokine-dependent
cell line. To this end, we transduced BaF3-EpoR cells and
selected for stable expression of wild-type or mutant-JAK2. As
expected,37,39,41 the R683G mutation can drive itself the prolifera-
tion of BaF3-EpoR cells, conferring cytokine independence as
assessed by cytokine withdrawal assays for at least four days in
cytokine-starving conditions. Proliferation of BaF3-EpoR cells in
the absence of exogenous cytokines was not observed in the case
of H574R or the wild-type JAK2 protein, but the number of viable
cells was signiﬁcantly higher in BaF3-EpoR cells expressing the
H574R mutant with regard to cells expressing the wild-type gene,
even after 4 days in the absence of cytokine (Figures 2b and c).
In cytokine-starving conditions, only R683G-JAK2 remains
phosphorylated and is able to induce STAT5 phosphorylation
(Figure 2d). This capacity can be sustained for at least 4 days
(Supplementary Figure S2). Furthermore, H574R and R683G
showed higher levels of JAK2 phosphorylation than wild-type
JAK2 in response to Epo stimulation after starving conditions
(Figure 2d).
JAK2 activation might be enhanced by hypermethylation of the
negative regulator SOCS3
Because epigenetic inactivation of three negative regulators of
JAK2 (SHP1, SOCS1 and SOCS3) have been reported in many
tumors,17,36,41,43–47 we determined the levels of CpG methylation
at the promoter regions of these genes in the three T-LBL samples
exhibiting missense mutations and the TEL-JAK2 translocation
(Figure 3).
Methylation-speciﬁc PCR showed that there was no signiﬁcant
aberrant hypermethylation in the CpG islands at the promoter
region of SHP1 and SOCS1 genes in any T-LBL sample. However,
we found aberrant hypermethylation of SOCS3 promoter in the
three samples (Figure 3b). Furthermore, bisulﬁte genomic
sequencing of 10 clones per sample conﬁrmed signiﬁcant
hypermethylation of SOCS3 with methylation densities ranging
from 45.2 to 94.8% (Figure 3c; Supplementary Table S3).
To assess whether SOCS3, SOCS1 and SHP-1 genes were
methylated in the T-LBL cases with intact JAK2 gene, we have
also evaluated gene methylation of these genes in the remaining
T-LBL samples. Methylation-speciﬁc PCR analysis revealed that
(i) SOCS1 is not hypermethylated in any T-LBL sample; (ii) SHP1 is
hypermethylated in only two lymphomas exhibiting intact JAK2
sequences (685 and 038); and (iii) aberrant hypermethylation of
SOCS3 is a primary event in T-LBL development. Using a cutoff of
20% methylation density, 7/10 lymphomas also exhibit signiﬁcant
hypermethylation of SOCS3 promoter. These results indicate that
aberrant hypermethylation of SOCS3 is not dependent on the
mutational status of JAK2 (Supplementary Figure S3).
To further validate whether promoter DNA hypermethylation is
involved in deregulating the expression of SOCS3, Jurkat cells
(which exhibit a high methylation density of about 93.7%) were
treated with 5-aza-2’-deoxycytidine. Signiﬁcant demethylation of
SOCS3 promoter was observed after treatment with 5-aza-2’-
deoxycytidine, which brings about SOCS3 upregulation at the
mRNA level. Treatments with trichostatin A, a histone deacetylase
inhibitor, produced only modest but signiﬁcant increases. How-
ever, the combination of both drugs seemed to be the most
successful treatment (Figure 4). These results were conﬁrmed
using the Molt-4 cell line (Supplementary Figure S4). So, we
propose that the aberrant promoter hypermethylation of SOCS3
Figure 4. Methylation analysis of SOCS3 in Jurkat cells. (a) Methyla-
tion proﬁle of the CpG island. The presence of methylated
black squares) or unmethylated (white squares) CpG sites is
indicated in 10 sequenced clones. Methylation density is indicated
as the percentage of methylated CpG sites. (b) Methylation-speciﬁc
PCR of untreated cells and cells treated with 5-aza-2´-deoxycitidine
(AZA) and trichostatin A (TSA). M, methylated; U, unmethylated; NL,
Normal lymphocytes; IVD, in vitro methylated DNA. (c) Levels of
mRNA expression of SOCS3 in treated and non-treated cells.
Quantitative real-time RT-PCR analysis of SOCS3 transcripts showed
signiﬁcant differences between treated and non-treated cells
(*Po0.05).
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we have detected in T-LBL samples might be contributing to a
partial inactivation of this gene and, consequently, to enhance
JAK2 activation in these primary lymphomas.
Next, we evaluated whether there exists a good match between
SOCS3 protein expression and methylation density at the
promoter region of this gene in primary T-LBLs. Remarkably,
some tumors exhibiting high levels of hypermethylation (238 and
734) also showed a very signiﬁcant reduction of SOCS3 protein.
However, other mechanisms than promoter hypermethylation
have to be considered in other cases (Supplementary Figure S5).
As previous reports had demonstrated high pSOCS3 levels in
speciﬁc mutant JAK2-bearing samples from myeloproliferative
neoplasms and in PCM1-JAK2-positive cells,32,48 we have also
studied the levels of endogenous SOCS3 tyrosine phosphorylation
induced by wild-type and two activating mutant JAK2 variants
(H574R and R683G). These analyses were performed in two
different experiments using BaF3-EpoR and γ2A cells according to
the protocols described by Elliot et al.32 However, we found no
signiﬁcant differences in the levels of phosphorylated SOCS3 that
can be attributed to these JAK2 mutations (see Supplementary
Figure S6)
All missense mutations induced a signiﬁcant increase of LMO2
expression
In addition to activating the canonical cytokine-signaling pathway,
a recent study demonstrated a non-canonical function for JAK2
activation as epigenetic regulator.24 In this article, the authors
demonstrated that a signiﬁcant proportion of JAK2 is present
within the nuclei of hematopoietic cells, which is able to increase
the expression of LIM domain Only 2 (LMO2) gene. Because LMO2
is a key oncogene operating in a fraction of T-cell lymphoblastic
leukemia/lymphomas,25–28 we investigated the possibility of a
mechanistic relationship between JAK2 mutations and the
expression of LMO2 in primary T-LBLs. Interestingly, the three
T-LBL samples harboring missense mutations or the TEL-JAK2
translocation (460, 734 and 829) exhibited signiﬁcant increases in
JAK2 and LMO2 expression.
To experimentally evaluate the relationship between JAK2
mutations and LMO2 expression, we analyzed (by qRT-PCR) the
levels of LMO2 in γ2A cells expressing with wild-type or mutant
JAK2 variants. Notably, all missense mutations were capable of
inducing signiﬁcant increases in the expression of LMO2 when
compared with the wild type. As there are no apparent differences
in JAK2 protein expression between wild-type and mutant JAK2
variants, this factor should not disturb the interpretation of the
data and their statistical signiﬁcance (Figure 5b). Confocal
immunoﬂuorescence in γ2A cells expressing wild-type or mutant
JAK2 variants revealed a signiﬁcant increase in the number of cells
exhibiting nuclear expression of mutant JAK2 proteins (Figures 6a
and b). This suggests that increased LMO2 expression may be
consistent with a greater presence of JAK2-mutant protein into
the nucleus. Notwithstanding, the type of mutation is another
factor to take into account, because no perfect matching can be
reached when the percentage of γ2A cells expressing nuclear
JAK2 and the levels of LMO2 expression are compared (Figures 5b
and 6b).
Immunohistochemistry analyses were performed with fresh
frozen tissue sections of two primary T-LBLs, one harboring wild-
type JAK2 (238) and the other bearing activating JAK2 mutations
(460). Remarkably, the presence of JAK2 into the nucleus was
more pronounced in lymphoma 460 (8.9% of cells) than in
lymphoma 238 (3.1%) (Figure 7).
DISCUSSION
At present, more than 30 mutations in the JH2 domain of JAK2
gene have been shown to be related with hematological
diseases,49 but the involvement of JAK2 in T-LBL is reduced to a
rare rearrangement resulting in the constitutively active TEL-JAK2
fusion oncoprotein.12 In the present article, we identiﬁed a
TEL-JAK2 translocation in one adult patient exhibiting an
immature T-LBL and validate the presence of four missense JAK2
sequence variants in the transcriptome of T-LBLs.
As the TEL-JAK2 fusion we found in patient 829 results from the
direct fusion of the Kinase (JH1) domain of JAK2 and the 5´ region
of the TEL gene (which contains an oligomerization domain), this
rearrangement should induce constitutive activation of the JAK-
STAT signaling pathway. In support of this notion, we found high
levels of phospho-STAT5 in this tumor (Figure 1). Noteworthy,
similar translocations reported in other tumors give rise to the
expression of an oncogenic protein that leads to constitutive
activation of the JAK2-STAT signaling pathway50 and is able to
induce cytokine-independent growth in the murine hematopoie-
tic cell line BaF3-EpoR.12 Furthermore, bone marrow trans-
plantation in mice using hematopoietic cells exogenously over-
expressing TEL-JAK2 results in mixed myeloproliferation and T-cell
lymphoproliferation.51 Interestingly, the TEL-JAK2 fusion-bearing
patient 829 suffers a ProT-lymphoblastic lymphoma that exhibits a
mixture of T-cell lymphoid and myeloid markers (CD3+, CD1a+,
MPO+; Supplementary Table S1).
In agreement with previous reports on other hematological
malignancies, JAK2 mutations found here accumulated in the
Figure 5. qRT-PCR analysis of JAK2 and LMO2 expression. (a) The
mean mRNA values of JAK2 and LMO2 in T-LBLs harboring JAK2
genetic alterations were normalized to those of a pool of fetal
thymuses. Data represent three independent replicates. Error bars
represent the s.d.; *Po0.01. A representative western blot of JAK2
can be seen under the bar chart. (b) The mean mRNA values of LMO2
in γ2A cells transiently transfected with mutant JAK2 variants were
normalized to that of wild-type JAK2-expressing cells. Data
represent three independent replicates. Error bars represent the
s.d.; *Po0.05 and **Po0.01.
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pseudokinase domain (JH2), which functionally prevents the
activation of the kinase domain (JH1).52 Two of the four missense
mutations had not been previously described for JAK2. Activating
R683G mutation has been previously described in B-cell acute
lymphoblastic lymphoma,37,39,41 thus serving as a point of
reference in our functional analyses. Notably, we have not
identiﬁed activating mutations at exon 14, where a gain-of-
function substitution (V617F) that is able to abrogate JH2 activity
in myeloproliferative neoplasms52,53 has been described in more
than 90% of patients with polycythemia vera.14–16 On the other
hand, we have identiﬁed novel sequence variants at exon 13 and
exon 15.
It should be noted, however, that all JAK2 mutations found are
accumulated in two pediatric patients (460 and 734) and that both
lymphomas exhibited three or more different variants with similar
pathogenic properties, suggesting sub-clonal heterogeneity
(Figure 1 and Supplementary Figure S1). Therefore, one can
speculate that an important fraction of lymphoma cells on each
mutated T-LBLs might be addicted to the activation of JAK2
pathway but not to any particular mutation. In addition, the fact
that the most common mutations (R683G and H574R) appeared in
a limited number of JAK2 transcripts, could explain that previous
reports have identiﬁed mutations in JAK1 and JAK3 but not in
JAK2.
In the case of lymphoma 460, R683G-JAK2 mutant is able to
activate the JAK2-STAT pathway in a constitutive manner, to
confer BaF3-EpoR cell line cytokine-independency and to induce a
signiﬁcant increase of LMO2 expression in transfected γ2A cells.
The other JAK2-mutation (I682T) is able to increase the expression
of LMO2 exclusively. In the case of lymphoma 734, mutant H574R
is able to activate the JAK2-STAT5 pathway, to drive the
proliferation of the cytokine-dependent cell line BaF3-EpoR and
to induce signiﬁcant increase in LMO2 expression. Thus, we could
hypothesize that different combinations of JAK2 mutations are
acting in concert to stimulate T-cell lymphoma development by
two different mechanisms: the activation of the canonical
cytokine-signaling pathway and the activation of LMO2, a key
oncogene in hematological malignancies. Taken together, these
results indicate that inhibition of JAK2 signaling using JAK pan-
inhibitors is a rational target for therapeutic intervention of T-LBLs
exhibiting activated JAK2.
On the other hand, the inhibition of SOCS3 seems to
facilitate tumor formation and growth in multiple human
cancers.35,54,55 Deletion of the SOCS3 gene has been reported in
liver parenchymal cells that promote hepatitis-induced
carcinogenesis;23 also, aberrant hypermethylation of CpG islands
in SOCS3 associated with reduced expression has been observed
Figure 6. Subcellular localization of JAK2 in γ2A cells transiently
expressing wild-type or mutant JAK2 variants. (a) Confocal
immunoﬂuorescence microscopy images identify JAK2 (green) in
γ2A cells expressing wild-type JAK2 or H574R, I682T and R683G JAK2
mutants, as representative. Nuclear staining was determined by
Topro (blue). (b) Histogram representing the quantiﬁcation of γ2A
cells positive for JAK2 cytosolic localization and positive for JAK2
nuclear and cytosolic localization, in percentage. γ2A cells transi-
ently expressing wild-type and every mutant JAK2 variant have been
analyzed; note that all mutants (H574R, L634P, I682T and R683G)
were signiﬁcantly more localized in the nucleus than the wild-type
JAK2. Error bars represent the s.d.; *Po0.05 and **Po0.01.
Figure 7. JAK2 nuclear localization in primary T-LBL samples.
(a) Sample 238 with intact JAK2 (left) and sample 460 harboring
several JAK2 mutant variants (right). Arrows indicate cells with
nuclear expression of JAK2. Magniﬁcation bar, 25 μm. (b) Histograms
showing the percentage of cells with cytosolic and nuclear
localization of JAK2.
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in various human cancers including several lymphoid
malignancies.56 Interestingly, we found aberrant hypermethyla-
tion at the promoter region of SOCS3 in the two T-LBL samples
exhibiting JAK2 mutations and in the sample with the TEL-JAK2
fusion protein. We therefore support that epigenetic inactivation
of SOCS3 might be a modulator event that should be considered
in T-LBLs. Interestingly, the epigenetic proﬁle of primary
lymphomas is similar to that exhibited by Jurkat cells (Figure 4).
Because treatment of Jurkat cells with 5-aza-2’-deoxycytidine
(5’-aza, decitabine) and histone deacetylase inhibitors signiﬁcantly
increase the expression of SOCS3, our data support that T-LBL
patients with hypermethylated SOCS3 might beneﬁt from
additional treatments with DNA methylation inhibitors, in
combination with histone deacetylase inhibitors. Furthermore,
because pharmacologic agents that block SOCS3 expression and
function may sensitize glioblastom multiform cells to ionized
radiation,57 the use of these drugs might ultimately improve the
effectiveness of radiotherapy in treating T-LBLs exhibiting activa-
tion of the JAK-STAT signaling pathway.
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